Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immunome Inc. Director's Dealing 2020

Oct 9, 2020

32238_dirs_2020-10-08_443261c2-5c3e-41f7-998b-0aee372152e2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2020-10-06

Reporting Person: MORRIS I WISTAR III (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-10-06 Common Stock C 882475 Acquired 882475 Direct
2020-10-06 Common Stock C 38464 Acquired 38464 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-10-06 Series A Convertible Preferred Stock $ C 882475 Disposed Common Stock (882475) Direct
2020-10-06 Series A Convertible Preferred Stock $ C 38464 Disposed Common Stock (38464) Indirect
2020-10-06 Warrant (right to buy) $9.00 C 111111 Disposed 2023-06-02 Series A Convertible Preferred Stock (111111) Direct
2020-10-06 Warrant (right to buy) $9.00 C 111111 Acquired 2023-06-02 Common Stock (111111) Direct

Footnotes

F1: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the
Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F2: The shares are held by Cotswold Foundation (the "Foundation"). the Reporting Person has voting and investment power with respect to shares held by the Foundation.

F3: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the
closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F4: Immediately exercisable.